Bloomage Biotech and Lumenis release postoperative care product to accelerate laser skin treatment recovery
Topscience Biotech supports free samples
The New Plant Summit and Award Ceremony for Nutritional Intelligence sponsored by New Nutrition was held in Guangzhou on December 17, 2021. New Nutrition has been deeply engaged in healthy nutrition industry for many years, based on the industry, to commit to link innovative raw materials and products and explore new strength for natural health industry.
The 2021 Fourth Food Science and Technology Innovation Forum and 2021 General Health Food Development Forum, which was sponsored by Food Partner Network and Food Industry Science and Technology magazine, was held in Longemont Hotel in Shanghai from April 20 to 21.Adhering to the tenet of scientific innovation and technological landing, the forum invited industry experts to analyze the research and development and innovation of the relative products from a professional perspective.
The National Health Commission issued an official announcement to approve the sodium hyaluronate declared by Bloomage Biotech as a new food raw material on January 7, 2021. Its application scope was milk and dairy products, beverages, alcohol, cocoa products, chocolate and chocolate products including cocoa butter substitute chocolate and its products, as well as candy and frozen drinks, excluding infant food.
Relief Reports that its U.S. Collaboration Partner’s Emergency Use Authorization Request for ZYESAMI®/RLF-100™ (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by the U.S. Food & Drug Administration
Huaxi Bio-acetylated Sodium Hyaluronate Hymagic™-AcHA won the Silver Award of InnoCosme InnoCosme Innovation Material and Formula Design Competition
Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., introduce in the US, TRILURON™ (sodium hyaluronate).
Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics
Promore Pharma has granted PharmaResearch Products the global license to commercialize PXL01 in the prevention of fibrosis after spinal surgery. The agreement sees PharmaResearch committing to fund development of the synthetic peptide in the indication and hand over milestones and royalties.